

AZU1

Native Human Azurocidin / CAP37

Catalog No.	CRA110A CRA110B	Quantity:	100 µg 1.0 mg
Alternate Names:	Azurocidin, Native Human Azurocidin / CAP37, Heparin-binding protein, HBP		
Description:	Azurocidin is a neutrophil granule-derived antibacterial and monocyte- and fibroblast-specific chemotactic glycoprotein. Binds heparin. The cytotoxic action is limited to many species of Gram-negative bacteria; this specificity may be explained by a strong affinity of the very basic N-terminal half for the negatively charged lipopolysaccharides that are unique to the Gram-negative bacterial outer envelope. It may play a role in mediating recruitment of monocytes in the second wave of inflammation. Has antibacterial activity against the Gram-negative bacterium <i>P.aeruginosa</i> , this activity is inhibited by LPS from <i>P.aeruginosa</i> .		
UniProt ID:	P20160		
Gene ID:	566		
Source:	Human neutrophils		
Molecular Weight:	37 kDa		
Formulation:	Lyophilized from a salt-free formulation.		
Purity:	≥ 95% by SDS-PAGE		
Extinction Coefficient:	$E_{280\text{nm}}^{0.1\%} = 0.51$		
Reconstitution:	Centrifuge vial prior to opening. Add sterile distilled water to a concentration of 0.1 -1.0 mg/mL and gently pipette the solution up and down the sides of the vial. DO NOT VORTEX. Allow several minutes for complete reconstitution.		
Storage & Stability:	Stable for 1 year at -20°C to -80°C. Avoid repeated freeze-thaw cycles.		
Infectious Disease Statement:	Prepared from whole blood shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.